MedPath

Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia

Conditions
Coagulation Disorder, Blood
Platelet Function
Registration Number
NCT03149250
Lead Sponsor
Goethe University
Brief Summary

The study aims to investigate the impact of preeclampsia on hemostasis.

Detailed Description

In comparison to healthy pregnant women and non-pregnant woman, this study analyses parameters of primary hemostasis and plasmatic coaguation in preeclamptic pregnant woman. Detailed analyses of the platelet function is performed using the Multiple Electrode Aggregometry, detailed analyses of the plasmatic coagulation syste is performed by isolated coaguation factor analyses and conventional coagulation analyses.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
60
Inclusion Criteria
  • Platelet count > 100 / nll
  • In study group and control group 1: Week of Pregnancy: 35-40
  • in control group 2: healthy, not pregnant woman
Exclusion Criteria
  • Hereditary coagulopathy
  • Missing content of the patient / proband
  • Eclampsia
  • HELLP syndrome
  • CRP > 1 mg/dl
  • Fever (> 38°C)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Area under the aggregation curve in the ADPtest of the Multiple Electrode AggregometryBetween 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

ADP induced platelet aggregation

Secondary Outcome Measures
NameTimeMethod
Area under the aggregation curve in the ASPItest of the Multiple Electrode AggregometryBetween 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

Arachidonic acid induced platelet aggregation

Area under the aggregation curve in the TRAPtest of the Multiple Electrode AggregometryBetween 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

Thrombin induced platelet aggregation

Parameters of plasmatic coagulation systemBetween 35th and 40th week of pregnancy; in control group 2 (not pregnant) within 1 week after inclusion into the study

von Willebrand Factor, Factor VIII, Factor XIII, parameter of conventional coagulation testing (apTT, INR, platelet count, Fibrinogen)

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.